Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel Brough

Showing results (1-10 of 66) with videos related to

Pageof 7
Sort By:
BMC Molecular Biology|May 12, 2007
Stringent and reproducible tetracycline-regulated transgene expression by site-specific insertion at chromosomal loci with pre-characterised induction characteristicsRachel Brough, Antigoni M Papanastasiou, Andrew C G Porter
Disability and Rehabilitation|May 22, 2025
Home is "a different planet" when transitioning from hospital after acquired brain injury: can digital technology help bridge the two worlds?Kaitlyn Spalding, Louise Gustafsson, Tenelle Hodson, et al.
Current Opinion in Genetics & Development|January 25, 2011
Searching for synthetic lethality in cancerRachel Brough, Jessica R Frankum, Sara Costa-Cabral, et al.
DNA Repair|September 8, 2007
Functional analysis of Drosophila melanogaster BRCA2 in DNA repairRachel Brough, Debbie Wei, Sophie Leulier, et al.
Oncotarget|April 18, 2015
Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivityJessica Frankum, Pavel Moudry, Rachel Brough, et al.
Brain Impairment : a Multidisciplinary Journal of the Australian Society for the Study of Brain Impairment|October 24, 2025
'I went home not feeling prepared from the outset': describing the co-design of a technological solution to address gaps in the transition from hospital to home for people with acquired brain injuryTenelle Hodson, Louise Gustafsson, Camila Shirota, et al.
EMBO Molecular Medicine|August 31, 2012
Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cellsIlirjana Bajrami, Asha Kigozi, Antoinette Van Weverwijk, et al.
The EMBO Journal|February 2, 2012
APRIN is a cell cycle specific BRCA2-interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancerRachel Brough, Ilirjana Bajrami, Radost Vatcheva, et al.
Cell Reports|February 2, 2018
Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast CancerAgnieszka K Witkiewicz, Sejin Chung, Rachel Brough, et al.
Human Mutation|February 1, 2012
Functional characterization of protein variants of the human multidrug transporter ABCC2 by a novel targeted expression system in fibrosarcoma cellsRudolf Arlanov, Andrew Porter, Dennis Strand, et al.
Pageof 7

Showing results (1-10 of 66) with videos related to

Sort By:
Pageof 7
BMC Molecular Biology|May 12, 2007
Stringent and reproducible tetracycline-regulated transgene expression by site-specific insertion at chromosomal loci with pre-characterised induction characteristicsRachel Brough, Antigoni M Papanastasiou, Andrew C G Porter
Disability and Rehabilitation|May 22, 2025
Home is "a different planet" when transitioning from hospital after acquired brain injury: can digital technology help bridge the two worlds?Kaitlyn Spalding, Louise Gustafsson, Tenelle Hodson, et al.
Current Opinion in Genetics & Development|January 25, 2011
Searching for synthetic lethality in cancerRachel Brough, Jessica R Frankum, Sara Costa-Cabral, et al.
DNA Repair|September 8, 2007
Functional analysis of Drosophila melanogaster BRCA2 in DNA repairRachel Brough, Debbie Wei, Sophie Leulier, et al.
Oncotarget|April 18, 2015
Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivityJessica Frankum, Pavel Moudry, Rachel Brough, et al.
Brain Impairment : a Multidisciplinary Journal of the Australian Society for the Study of Brain Impairment|October 24, 2025
'I went home not feeling prepared from the outset': describing the co-design of a technological solution to address gaps in the transition from hospital to home for people with acquired brain injuryTenelle Hodson, Louise Gustafsson, Camila Shirota, et al.
EMBO Molecular Medicine|August 31, 2012
Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cellsIlirjana Bajrami, Asha Kigozi, Antoinette Van Weverwijk, et al.
The EMBO Journal|February 2, 2012
APRIN is a cell cycle specific BRCA2-interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancerRachel Brough, Ilirjana Bajrami, Radost Vatcheva, et al.
Cell Reports|February 2, 2018
Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast CancerAgnieszka K Witkiewicz, Sejin Chung, Rachel Brough, et al.
Human Mutation|February 1, 2012
Functional characterization of protein variants of the human multidrug transporter ABCC2 by a novel targeted expression system in fibrosarcoma cellsRudolf Arlanov, Andrew Porter, Dennis Strand, et al.
Pageof 7